https://twitter.com/renalandurology/status/1722302970010747251Zibotentan, a selective endothelin A receptor antagonist, may further reduce albuminuria in patients with chronic #kidneydiseases (CKD) when added to SGLT2 inhibitor therapy, investigators reported at #KidneyWk. https://bit.ly/49stfTV
— Renal & Urology News (@renalandurology) Nov 8, 2023
Wednesday, November 8, 2023
@renalandurology
http://twitter.com/renalandurology
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment